Related Experiment Video
Updated: Aug 27, 2025
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
Preclinical evaluation of a microparticle-based transdermal vaccine patch against metastatic breast cancer
Rokon Uz Zaman1, Rikhav P Gala1, Amit Bansal1
1Vaccine Nanotechnology Laboratory, Mercer University, Atlanta, GA 30341, United States.
Abstract:
Breast cancer is the number one cause of cancer-related deaths among females. Current chemotherapy targets both tumor and normal cells, leading to pronounced side effects. Therefore, therapeutic vaccines acting against specific cancer cells would be the choice of treatment. We prepared microparticles entrapping the antigens obtained from a murine metastatic breast cancer cell line, 4 T1 using the spray drying technology. These microparticles were incorporated into microneedle patches to deliver to the animals for the efficacy study. An antineoplastic drug, cyclophosphamide, in a very low dose has been found to inhibit the immunosuppressive regulatory T cells (Treg) (Le and Jaffee, 2012). In-vivo efficacy of the microparticulate vaccine given along with a low dose of cyclophosphamide was evaluated in a murine breast cancer model. Animals immunized with vaccine microparticles showed considerably slower tumor growth than animals that did not receive the vaccine. The results of the study showed that the Tumor-Associated Antigens (TAAs) within the microparticles were responsible for the delayed tumor growth in vaccinated animals. Vaccinated animals also showed an increase in the population of CD4 and CD8 T cells. Overall, our results demonstrated that immunotherapy with vaccine microparticles encapsulating TAA's could potentially be an effective treatment for metastatic breast cancer.
Insights
This study developed microparticle vaccines from breast cancer cells to treat metastatic cancer. Vaccinated mice showed slower tumor growth and increased T cells, indicating a promising immunotherapy approach.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Breast cancer is a leading cause of female cancer deaths, with chemotherapy causing significant side effects.
- Therapeutic vaccines targeting specific cancer cells offer a promising alternative treatment strategy.
- Regulatory T cells (Treg) can suppress anti-tumor immune responses.
Purpose of the Study:
- To evaluate the in-vivo efficacy of microparticle-encapsulated tumor-associated antigens (TAAs) as a therapeutic vaccine for metastatic breast cancer.
- To investigate the combined effect of this vaccine with low-dose cyclophosphamide, an inhibitor of Treg cells.
- To assess the impact on tumor growth and immune cell populations in a murine model.
Main Methods:
- Microparticles encapsulating TAAs from the 4T1 murine breast cancer cell line were prepared using spray drying technology.
- These microparticles were formulated into microneedle patches for vaccination.
- The efficacy of the microparticulate vaccine, with and without low-dose cyclophosphamide, was tested in a murine breast cancer model.
Main Results:
- Animals vaccinated with microparticle-encapsulated TAAs exhibited significantly slower tumor growth compared to unvaccinated controls.
- The vaccine demonstrated efficacy in delaying tumor progression in the metastatic breast cancer model.
- Vaccinated animals showed an increased population of CD4 and CD8 T cells, suggesting an enhanced immune response.
Conclusions:
- Microparticle-encapsulated TAAs hold potential as an effective immunotherapy for metastatic breast cancer.
- The combination of this vaccine with low-dose cyclophosphamide may enhance anti-tumor immunity.
- This approach offers a targeted strategy to combat breast cancer with potentially reduced side effects compared to traditional chemotherapy.
